SCHEMBL12151683

SCHEMBL12151683

O=C(O)c1ccc(Nc2cccc(Cl)c2)cc1OCc1cccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.61
▸ MEN1 O00255 6/20 0.49
▸ KMT2A Q03164 6/20 0.49
▸ TRPM4 Q8TD43 1/20 0.47
▸ POLB P06746 2/20 0.47
▸ G6PD P11413 1/20 0.47
▸ LMNA P02545 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ ALPG P10696 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ AKR1C3 P42330 1/20 0.47
▸ AKR1C2 P52895 1/20 0.47
▸ MRGPRX4 Q96LA9 3/20 0.46
▸ PARP15 Q460N3 1/20 0.46
▸ PARP10 Q53GL7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1377745 0.92 FDPS (0.67) FDPSMEN1KMT2ALMNAPARP15
SCHEMBL12151726 0.86 FDPS (0.60) FDPSMEN1KMT2ATRPM4POLB
SCHEMBL12151685 0.86 FDPS (0.65) FDPSMEN1KMT2APOLBLMNA
SCHEMBL12151682 0.86 FDPS (0.64) FDPSMEN1KMT2ALMNAPARP15
SCHEMBL12151546 0.85 FDPS (0.62) FDPSMEN1KMT2APOLBLMNA
SCHEMBL12151725 0.85 FDPS (0.61) FDPSMEN1KMT2ALMNACYP2C9
SCHEMBL12151689 0.85 FDPS (0.58) FDPSMEN1KMT2APARP15PARP10
SCHEMBL12151723 0.83 FDPS (0.64) FDPSMEN1KMT2APOLBLMNA
SCHEMBL12151687 0.82 FDPS (0.63) FDPSMEN1KMT2APOLBLMNA
SCHEMBL12151679 0.82 FDPS (0.60) FDPSMEN1KMT2ALMNAPARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
WO-2010043584-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS FDPS, GGPS1, COASY FDPS 1/4885MEN1 2332/4885KMT2A 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback